Compare Dover Corp (DOV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs BIO-TECHNE Corp — how do they compare? Dover Corp trades at $216.11 (market cap $28.85B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Dover Corp is far larger — about 2.6× BIO-TECHNE Corp's market cap, and Dover Corp pays the higher dividend (0.97%). Which is the better fit depends on your goals.
| DOV | TECH | |
|---|---|---|
Market Cap | $28.85B | $11.12B |
Sector | Industrials | Health |
52-Week High | $233.31 | $71.38 |
52-Week Low | $161.16 | $43.31 |
Enterprise Value | $30.50B | $11.20B |
Dividend Yield | 0.97% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
